PMDA drug package insert

エンタイビオ皮下注108mgペン

PMDA Prescription drug · 武田薬品工業株式会社 · package insert Oct 1, 2026

Key facts

Brand names エンタイビオ皮下注108mgペン, エンタイビオ皮下注108mgシリンジ
Nonproprietary names ベドリズマブ(遺伝子組換え)
Companies 製造販売(輸入)元/武田薬品工業株式会社
Product type Prescription drug
Therapeutic category ヒト化抗ヒトα4β7インテグリンモノクローナル抗体製剤
Therapeutic category codes 872399
YJ codes 2399405G2021, 2399405G1025
Approval numbers 30500AMX00103, 30500AMX00104
Package insert edition 第7版
Package insert date Oct 1, 2026
PMDA document key 400256_2399405G1025_1
PMDA company code 400256

At a glance

  • 1–9 Package insert revisions
  • 10–99 Related PMDA documents
  • None Safety communications
  • Yes PMDA review report published
  • Yes Risk management plan (RMP)

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMDA approved drugs and package inserts (Japan)

Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.

Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date:

Browse all PMDA approved drugs and package inserts (Japan)